Recruiting OBSERVATIONAL NCT07365930
NIS on the Benefits of TIPS in Patients With HCC Receiving Atezo+Bev in 1st-Line Therapy (NISTIPS)
Non-Interventional Study on the Benefits of Transjugular Intrahepatic Portosystemic Shunting in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab in First-Line Therapy
Sponsor: Heinrich-Heine University, Duesseldorf
Conditions
Hepatocellular Carcinoma (HCC)
Updated 1 time since 2026 Last updated: Feb 3, 2026 Started: Dec 17, 2025 Primary completion: Dec 17, 2031 Completion: Dec 17, 2031
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
This observational or N/A phase trial investigates Hepatocellular Carcinoma (HCC) and is currently actively recruiting participants. Heinrich-Heine University, Duesseldorf leads this study, which shows 1 recorded version since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
1 version recorded Recruiting
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Heinrich-Heine University, Duesseldorf
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Roche Pharma AG
Data source: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
For direct contact, visit the study record on ClinicalTrials.gov .